Our team of professionals and staff believe that informed patients are better equipped to make decisions regarding their health and well-being. For your personal use, we have created an extensive patient library covering an array of educational topics, which can be found on the side of each page. Browse through these diagnoses and treatments to learn more about topics of interest to you.
As always, you can contact our office to answer any questions or concerns.
Are you receiving targeted therapy to treat skin cancer — or any other cancer? If so, dermatologists recommend that you pay close attention to your skin.
Skin reactions are the most common side effect of targeted therapy.
When cancer spreads and becomes life threatening, drugs known as targeted therapies may be an option for some patients. Targeted therapy can stop cancer from growing and spreading — at least for a while.
Oncologists (cancer doctors) prescribe target therapy to treat some skin cancers. It may be prescribed to treat melanoma, the most-serious skin cancer, when it spreads. Targeted therapy can also treat basal cell carcinoma (BCC), the most-common skin cancer. It may be prescribed when BCC has spread and surgery or radiation treatments can no longer treat it.
Some patients with dermatofibrosarcoma protuberans (DFSP), a rare type of skin cancer, also receive targeted therapy.
Targeted therapy can give cancer patients remissions that last for months — and sometimes years.
Paying close attention to your skin will help you notice the first signs of a skin reaction.
Even if the reaction seems mild, it’s important to tell your dermatologist or oncologist about it. When caught early, most reactions can be managed.
Looking closely at your skin will also help you find a possible new skin cancer early. Although targeted therapies can treat advanced skin cancer, some can cause more skin cancers. Caught early, most skin cancers can be successfully treated.
Early treatment of a skin reaction can also help prevent a worsening reaction. If the skin reaction becomes too severe, a patient may have to stop targeted therapy.
To give you an idea of what you may see, here’s a list of common skin reactions from the targeted therapies approved to treat skin cancer.
Dabrafenib (Tafinlar®) or vemurafenib (Zelboraf®) – Prescribed to treat advanced melanoma, the most common skin (and hair) reactions from these drugs are:
More serious skin reactions are:
Trametinib (Mekinist®) – This may be prescribed to treat advanced melanoma. Common skin (and hair) reactions that occur while taking trametinib include:
Ipilimumab (Yervoy®), nivolumab (Opdivo®), or pembrolizumab (Keytruda®) – Patients with advanced melanoma may be prescribed one of these targeted therapies, which can cause the following skin reactions:
Vismodegib (Erivedge®) – Prescribed to treat advanced basal cell carcinoma, some patients experience the following side effects:
The right skin care can reduce your risk of developing some skin reactions. If a skin reaction develops, good skin care may lessen your discomfort. That’s why dermatologists recommend the following skin care for patients on a targeted therapy:
To keep your skin care gentle, dermatologists also recommend that you:
You want to apply the sunscreen to all skin that clothing won’t cover, such as your face, neck, ears, and hands. A separate lip balm with SPF 30 or higher and water resistance is best for your lips. You’ll want to apply sunscreen and lip balm thoroughly to give yourself good protection.
Because skin reactions are so common, some patients see a dermatologist before starting targeted therapy. It can be helpful to have a thorough skin exam and get skin care tips beforehand.
If you develop a skin reaction, it’s helpful to have a skin expert to contact for a diagnosis and treatment.
Image of vitiligo: Thinkstock
Collins LK, Chapman MS, et al. “Cutaneous adverse effects of the immune checkpoint inhibitors.” Curr Probl Cancer. 2016 Dec 14. [Epub ahead of print].
Macdonald JB, Macdonald B, et al. “Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203-18.
Macdonald JB, Macdonald B, et al. “Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.” J Am Acad Dermatol. 2015 Feb;72(2):221-36.
Patterson S, “Cutaneous reactions to targeted therapy.” Presented during focus session: Update on cutaneous reactions to targeted and immune cancer therapies. 2017 Annual Meeting of the American Academy of Dermatology; 2017 March 3-7. Orlando, FL.
Sibaud, V, Meyer N. et al. “Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.” Curr Opin Oncol. 2016;28(4):254-63.